3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts AheadMarketBeat · Oct 10, 2026
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research · Oct 5, 2026
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating OfficerGlobeNewsWire · Sep 29, 2026
5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryZacks Investment Research · Sep 14, 2026
BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMRDefense World · Sep 4, 2026
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from BrokeragesDefense World · Aug 31, 2026Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.38 | -$0.30 | Beat |
| May 14, 2026 | -$0.53 | -$0.31 | Beat |
| Mar 19, 2026 | -$0.44 | -$0.73 | Miss |
| Nov 5, 2025 | -$0.39 | -$0.61 | Miss |
| Aug 14, 2025 | -$0.47 | -$0.41 | Beat |
| Apr 30, 2025 | -$0.42 | -$0.46 | Miss |